收稿日期: 2020-03-19
网络出版日期: 2022-12-19
基金资助
北京大学口腔医院青年科研基金(PKUSS20160115);国家自然科学基金(81900979)
Analysis of pathological characteristics of medication-related osteonecrosis of the jaw and discussion of clinical treatment strategies based on the pathological analysis results
Received date: 2020-03-19
Online published: 2022-12-19
Supported by
the Research Foundation of Peking University School and Hospital of Stomatology(PKUSS20160115);the National Natural Science Foundation of China(81900979)
目的: 总结药物相关颌骨骨坏死(medication-related osteonecrosis of the jaw, MRONJ)标本病理特点,结合患者不同手术方案治疗效果进行综合分析,为临床工作中有效治疗MRONJ提供思路。方法: 收集2014年6月至2015年12月北京大学口腔医院口腔颌面外科采用颌骨刮治术和颌骨区段截骨术进行治疗的23例MRONJ患者临床病理资料,总结MRONJ病理特点,并结合手术治疗方式,探讨基于病理表现特征下的临床治疗策略。MRONJ诊断标准和疾病分期依据2014年美国口腔颌面外科学会专家共识进行判定。结果: 本组患者5例采用颌骨区段截骨治疗,均为Ⅲ期;18例采用颌骨刮治治疗,其中Ⅱ期5例,Ⅲ期13例。5例颌骨区段截骨术的MRONJ标本病理特征从浅至深分为炎症区、骨硬化区、骨反应带,为更好分析颌骨刮治术的标本病理表现特征,我们将仅包括炎症区的表现定义为Ⅰ类病理特征,包括炎症区和骨硬化区的表现定义为Ⅱ类病理特征,而包括炎症区、骨硬化区和骨反应带的表现定义为Ⅲ类病理特征。18例颌骨刮治术患者病理特征分布如下:Ⅰ类38.9%(7/18),Ⅱ类44.4%(8/18),Ⅲ类16.7%(3/18)。5例患者采用颌骨区段截骨术治疗,术后完全愈合。18例患者采用颌骨刮治术治疗,术后完全愈合的患者中病理特征分别为Ⅰ类2例,Ⅱ类和Ⅲ类各1例;而术后出现MRONJ复发的患者中病理特征分别为Ⅰ类5例,Ⅱ类7例和Ⅲ类2例。结论: MRONJ病变由浅至深的病理表现可分为炎症区、骨硬化区、骨反应带;颌骨刮治术治疗MRONJ复发的常见原因可能为术中未充分去除骨硬化区,而遗留的骨硬化区可能阻断了骨创愈合所需要的血运、营养因子及间充质干细胞。
郭玉兴 , 张建运 , 王佃灿 , 郭传瑸 . 药物相关颌骨骨坏死的病理特点及临床治疗策略[J]. 北京大学学报(医学版), 2022 , 54(6) : 1190 -1195 . DOI: 10.19723/j.issn.1671-167X.2022.06.022
Objective: To summarize the pathological characteristics of medication-related osteonecrosis of the jaw (MRONJ) specimens after jaw curettage or jaw osteotomy treatment and to comprehensively analyze the relationship between the different pathological features, treatment methods, and treatment effects to provide new ideas for effective treatment of MRONJ in clinical work. Methods: The clinical and pathological data were collected from 23 patients with MRONJ who were treated with curettage (18 patients) and jaw osteotomy (5 patients) at the Department of Oral and Maxillofacial Surgery of Peking University Hospital of Stomatology between June 2014 and December 2015. The pathological characteristics of MRONJ were summarized and analyzed with treatment effects based on various surgical treatment methods. The diagnostic criteria and disease staging of MRONJ were determined according to the 2014 American Association of Oral and Maxillofacial Surgeon's Position Paper. Results: In this study, 5 patients have treated with jaw segmental osteotomy, and all of them were in stage Ⅲ; the other 18 patients were treated with jaw curettage, including 5 patients in stage Ⅱ and 13 patients in stage Ⅲ. The pathological features of MRONJ in five cases of jaw segmental osteotomy were divided into three adjacent regions from shallow to deep: inflammation region (IR), sclerosis region (SR), and bone remodeling layer (BRL). Moreover, three types of pathological features of specimens from traditional curettage were defined as type 1 (IR), type 2 (IR + SR), and type 3 (IR + SR + BRL). The pathological features of the patients treated with jaw curettage were: type Ⅰ, 38.9% (7/18); type Ⅱ, 44.4% (8/18); type Ⅲ, 16.7% (3/18). Complete healing was achieved in 5 patients treated with jaw segmental osteo-tomy. Moreover, 2 cases with type Ⅰ, 1 case with type Ⅱ, and 1 with type Ⅲ completely healed after jaw curettage, while 5 cases with type Ⅰ, 7 cases with type Ⅱ, and 2 cases with type Ⅲ experienced recurrence after surgery. Conclusion: Pathological features of continuous regions of inflammation, sclerosis, and bone remodeling layer were identified from shallow to deep, based on the microscopic observation of jaw segmental osteotomy samples. Insufficient removal of the sclerotic region during jaw curettage that blocks the required blood, nutritional factors, and mesenchymal stem cells seems to be a common cause for failed treatment of MRONJ after curettage surgery.
| 1 | Sacco R , Sacco N , Hamid U , et al. Microsurgical reconstruction of the jaws using vascularised free flap technique in patients with medication-related osteonecrosis: A systematic review[J]. Biomed Res Int, 2018, 2018, 9858921. |
| 2 | Rupel K , Ottaviani G , Gobbo M , et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)[J]. Oral Oncol, 2014, 50 (11): 1049- 1057. |
| 3 | 郭玉兴, 王佃灿, 王洋, 等. 二膦酸盐药物治疗乳腺癌骨转移发生颌骨坏死的临床特点[J]. 北京大学学报(医学版), 2016, 48 (1): 80- 83. |
| 4 | Hayashida S , Soutome S , Yanamoto S , et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis[J]. J Bone Miner Res, 2017, 32 (10): 2022- 2029. |
| 5 | Ruggiero SL , Dodson TB , Fantasia J , et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update[J]. J Oral Maxillofac Surg, 2014, 72 (10): 1938- 1956. |
| 6 | Basi DL , Hughes PJ , Thumbigere-Math V , et al. Matrix metalloproteinase-9 expression in alveolar extraction sockets of Zoledronic acid-treated rats[J]. J Oral Maxillofac Surg, 2011, 69 (11): 2698- 2707. |
| 7 | Yamashita J , Koi K , Yang DY , et al. Effect of zoledronate on oral wound healing in rats[J]. Clin Cancer Res, 2011, 17 (6): 1405- 1414. |
| 8 | Marx RE . Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61 (9): 1115- 1117. |
| 9 | Ruggiero SL , Mehrotra B , Rosenberg TJ , et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases[J]. J Oral Maxillofac Surg, 2004, 62 (5): 527- 534. |
| 10 | Lin JT , Lane JM . Bisphosphonates[J]. J Am Acad Orthop Surg, 2003, 11 (1): 1- 4. |
| 11 | Di Fede O , Panzarella V , Mauceri R , et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention[J]. Biomed Res Int, 2018, 2018, 2684924. |
| 12 | Shintani T , Hayashido Y , Mukasa H , et al. Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates[J]. Int J Oral Maxillofac Surg, 2015, 44 (7): 840- 844. |
| 13 | Nicolatou-Galitis O , Papadopoulou E , Vardas E , et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents[J]. Oral Dis, 2020, 26 (5): 955- 966. |
| 14 | Guo Y , Guo C . Enhancement of bone perfusion through cortical perforations to improve healing of medication-related osteonecrosis of the jaw: A retrospective study[J]. Int J Oral Maxillofac Surg, 2021, 50 (6): 740- 745. |
| 15 | 郭玉兴, 王佃灿, 刘筱菁, 等. 翻瓣联合骨管技术拔牙方案在药物相关性颌骨坏死潜在风险患者中的应用初探[J]. 中华口腔医学杂志, 2021, 56 (5): 452- 457. |
/
| 〈 |
|
〉 |